The identification of actionable molecular abnormalities in MM such as BRAF mutations, along with the development of BRAF inhibitors, suggests the possibility of patient-tailored treatments targeting clonal plasma cells with a specific oncogenomic profile [7,8,9,10,11]. This evidence concerns the gene BRAF and Miyoshi myopathy.